Supplementary Figure S8 from Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal Ctdna and Immune Cell Compartment Tracking in Lung Cancer

Supplementary Fig.S8 Overview of peripheral blood TCR dynamics in patients with immunotherapy-related pneumonitis. (A) Swimmer plot showing treatment duration for 17 patients with immune-related toxicity and paired baseline and on-treatment blood samples available for analysis. The time to identification of significant TCR clonotypic expansions and regressions in first on-treatment blood samples is shown alongside the time to clinical diagnosis of toxicity. Overall, TCR clonotype dynamics were identified on average 20 weeks prior to the clinical presentation of immune-related toxicity in these patients. (B-E) Logo plots showing global TCR clusters identified using GLIPH2 that were significantly expanded in on-therapy peripheral blood samples from patients who developed pneumonitis compared to individuals who developed other immune-related adverse events (irAEs) and individuals who did not develop immune-related toxicity. The size of each cluster, defined by the number of distinct CDR3 member sequences, is indicated alongside each panel. Enriched clusters with a minimum motif length of 5 are shown. (F-G) Boxplots showing the differential abundance of TCR clusters shown in (C-E) from baseline to on-treatment samples across patient groups.